1004316-88-4 | 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$38.00	$27.00
5mg	97%	in stock	$157.00	$110.00
10mg	97%	in stock	$277.00	$194.00
100mg	97%	in stock	$713.00	$499.00
250mg	97%	in stock	$1,179.00	$825.00
1g	97%	in stock	$2,578.00	$1,805.00

Description

• Catalog Number: AA02367
• Chemical Name: 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[(2S)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate
• CAS Number: 1004316-88-4
• Molecular Formula: C40H53N7O5S2
• Molecular Weight: 776.0227
• MDL Number: MFCD18251449
• SMILES: O=C(N[C@@H](Cc1ccccc1)CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1

Computed Properties

• Complexity: 1120
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 54
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 20
• XLogP3: 5.7

Upstream Synthesis Route

2,7,10,12-Tetraazatridecanoic acid, 12-methyl-13-[2-(1-methylethyl)-4-thiazolyl]-9-[2-(4-morpholinyl)ethyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3R,6R,9S)- is a complex compound that plays a crucial role in chemical synthesis processes. This compound is commonly utilized in the creation of intricate molecular structures due to its unique combination of functional groups and stereochemistry. Its specific arrangement of atoms allows for precise manipulation and control of chemical reactions, making it a valuable tool in the synthesis of various organic molecules with specific properties and functions.

Literature

• Pharmacokinetic enhancers in HIV therapeutics.

  Clinical pharmacokinetics 20141001

• Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.

  Antimicrobial agents and chemotherapy 20121001

• Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

  Journal of acquired immune deficiency syndromes (1999) 20120901

• Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

  Expert opinion on pharmacotherapy 20120901

• [A single tablet against HIV: new combination preparation improves therapy].

  Deutsche medizinische Wochenschrift (1946) 20120801

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  Lancet (London, England) 20120630

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

  Lancet (London, England) 20120630

• Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

  AIDS (London, England) 20110924

• Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

  AIDS (London, England) 20110327

• Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.

  Journal of acquired immune deficiency syndromes (1999) 20101101

• Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

  ACS medicinal chemistry letters 20100812

• Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

  Clinical pharmacology and therapeutics 20100301